Clinical Trials in Houston

Showing 2661-2680 of 8,625 trials

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

NCT04432506

This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Anakinra is a drug typically used to treat rheumatoid arthritis but may also help in reducing CAR-T cell therapy toxicity. Giving anakinra in combination with axicabtagene ciloleucel may help control relapsed or refractory large B-cell lymphoma.

Hematopoietic and Lymphoid Cell NeoplasmRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+6 more

M.D. Anderson Cancer Center22 participantsStarted Jul 2020

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01718743

This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.

Hematopoietic Cell Transplantation RecipientPlasma Cell Myeloma

M.D. Anderson Cancer Center64 participantsStarted Dec 2012

Houston, Texas, United States

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Find Trials by Condition in Houston

Single Step Lesion Annotation and Localization of Suspicious Breast Lesions

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia

Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma

Novel Experimental COVID-19 Therapies Affecting Host Response

Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Intermediate Expanded Access Protocol CNMAu8.EAP04

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)